European Pharmaceutical Review Issue 3 2021

In this journal, features on the current regulatory positions on nitrosamine impurities, how investing in off-patent medicines can help drive innovation and why new regulations could lead to a biosimilar boom in the UK. Other articles include an exploration of the challenges in developing and delivering lipid nanoparticle mRNA-based vaccines, how software can be used to improve pharma development output and so much more…

EPR Featured Image

Issue 3 also features:

    O-glycan analysis of therapeutic proteins enabled by O-glycoprotease
    Xiaofeng Shi, Saulius Vainauskas and Christopher H Taron, New England Biolabs (NEB)
  • NMR
    Solid- and Liquid-State NMR for monitoring of polysaccharide antigen in the manufacturing process
    Francesco Berti, GSK Vaccines
    The role of digital transformation in achieving Pharma 4.0
    Saly Romero-Torres, Thermo Fisher Scientific

This issue also includes our Application Note Supplement 2021:

  • Software that makes Data Integrity Compliance visible: Shimadzu LabSolutions database (DB) or client/server software (CS) combining reliability and productivity
  • The Monocyte Activation Assay: The benefits of an animal-free test to show pyrogen-free pharmaceutical products
    Nelson Labs
  • From our platforms to your pen injector

The rest of this content is restricted - login or subscribe free to access

Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here